Treatment of head and neck cancer
AssigneeInnate Pharma
InventorsAgnes BOYER-CHAMMARD, Pierre DODION, Roger COHEN
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of NKG2A-targeting agents for the treatment of cancers, notably head and neck cancers, in a patient having received prior treatment with cetuximab. This invention also provides advantageous combination regimens for use with NKG2A-targeting agents for the treatment of cancers.
Claims27
An agent that neutralizes the inhibitory activity of human NKG2A, for use in the treatment of a HNSCC in an individual having received prior treatment with cetuximab.
The agent for use of any one of the above claims, wherein the individual has a HNSCC cancer that has progressed despite prior treatment with cetuximab combined with radiotherapy or chemotherapy.
The agent for use of any one of the above claims, wherein the individual has a HNSCC cancer that has progressed despite prior treatment with cetuximab as single agent.
The agent for use of any one of the above claims, wherein the individual has unresectable HNSCC.
The agent for use of any one of the above claims, wherein the agent that neutralizes the inhibitory activity of human NKG2A is administered in combination with cetuximab.
Cetuximab, for use in the treatment of a HNSCC in an individual having received prior treatment with cetuximab, wherein said treatment comprises administering to the individual an effective amount of each of:
- (a) an agent, optionally an antibody, that neutralizes the inhibitory activity of human NKG2A, and (b) cetuximab.
An agent that neutralizes the inhibitory activity of human NKG2A for use in treating a cancer in a human individual having an unresectable, optionally non-metastatic, HNSCC, optionally wherein the HNSCC is cetuximab-resistant, the treatment comprising administering to the individual an effective amount of each of:
- (a) an agent, optionally an antibody, that neutralizes the inhibitory activity of human NKG2A, and (b) cetuximab.
The agent for use of any one of the above claims, wherein the individual has HNSCC cancer that has progressed despite prior treatment with cetuximab.
The agent for use of any one of the above claims, wherein the individual has HNSCC cancer that has progressed despite prior treatment with cetuximab combined with radiotherapy.
The agent for use of any one of the above claims, wherein the treatment of a HNSCC in an individual comprises:
- a) determining whether an individual has a HNSCC that is resistant to cetuximab (e.g. as single agent or in combination with radiotherapy and/or a chemotherapeutic agent), and
- b) upon the determination that the individual has HNSCC that is resistant to cetuximab, administering to the individual:
- (i) an agent, optionally an antibody, that neutralizes the inhibitory activity of human NKG2A, and (ii) cetuximab.
The agent for use of any of the above claims, wherein the treatment of a HNSCC in an individual comprises:
- a) determining whether HLA-E polypeptide is expressed by malignant cells from the individual having a HNSCC, and
- b) upon the determination that malignant cells express HLA-E polypeptide, administering to the individual (i) an agent, optionally an antibody, that neutralizes the inhibitory activity of human NKG2A, and ii) cetuximab.
The agent for use of any one of the above claims, wherein the agent that neutralizes the inhibitory activity of human NKG2A is an anti-NKG2A antibody.
The agent for use of any one of the above claims, wherein the anti-NKG2A antibody is administered several times at a dosing frequency from once about every week to once about every month.
The agent for use of any one of the above claims, wherein cetuximab is administered weekly.
The agent for use of any one of the above claims, wherein the treatment comprises at least one administration cycle, wherein the agent that neutralizes the inhibitory activity of human NKG2A is administered every two weeks and cetuximab is administered weekly.
The agent for use of any one of the above claims, wherein the treatment comprises at least one period of two weeks, wherein for each of the at least one period, the antibody that neutralizes the inhibitory activity of human NKG2A is administered at a dose of 1-10 mg/kg body weight, and cetuximab is administered in an initial dose of 400 mg/m2, and subsequently weekly at 250 mg/m2.
The agent for use of any one of the above claims, wherein the treatment comprises at least one period of two weeks, wherein for each of the at least one period, the antibody that neutralizes the inhibitory activity of human NKG2A is administered at a fixed dose between 100-1000 mg, optionally 750 mg, and cetuximab is administered in an initial dose of 400 mg/m2, and subsequently weekly at 250 mg/m2.
Dependencies are inferred from the claim text.